EVO

Business Context and Reporting Period

Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and nine months ended September 30, 2008
Business Overview: Evotec is a drug discovery and development company focusing on proprietary CNS (Central Nervous System) pipelines and research collaborations. The period includes the consolidation of Renovis, Inc. (acquired May 2, 2008) and excludes the Chemical Development Business (sold November 2007, reported as discontinued operations).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 9% year-over-year for the nine-month period (18% at constant currencies). The Q3 revenue surge of 44% was primarily driven by milestone payments from the Boehringer Ingelheim collaboration.
• Margin Expansion: Gross margin improved significantly from 20.0% to 38.0% (nine months) due to high-margin milestone revenues and lower cost of revenues.
• Expense Management: Operating loss narrowed despite an 18% increase in R&D expenses (driven by the Renovis acquisition and clinical pipeline progress). Amortization of intangible assets decreased 78% year-over-year.
• Non-Operating Income: Net loss reduction was aided by EUR 5.1 million in other income from financial assets, specifically the revaluation of Direvo convertible bonds following the sale of Direvo Biotech to Bayer HealthCare.
• Acquisition Impact: Results include Renovis, Inc. operations from May 2, 2008, making direct comparisons with 2007 continuing operations limited.

Guidance, Outlook, and Risks

Updated 2008 Financial Guidance

• Revenue: Raised to EUR 38–40 million (previously EUR 34–36 million) due to higher-than-anticipated milestones from Boehringer Ingelheim.
• R&D Expenses: Lowered to EUR 40–45 million (previously EUR 46–51 million) due to reduced discovery spend and cost containment.
• Liquidity: Year-end cash and investments target increased to EUR 90–95 million (previously >EUR 80 million), sufficient to fund operations through 2010 absent major partnering events.

Management Commentary & Pipeline

• Clinical Progress: Five compounds in clinical development. EVT 302 entered Phase II for smoking cessation; EVT 101 preparing for Phase II in pain; Phase I initiated for P2X7 antagonist (inflammation) and VR1 antagonist (pain, with Pfizer).
• Partnerships: Discussions advanced for EVT 201 (insomnia) with a potential contract expected in early 2009. Two additional Boehringer Ingelheim milestones (EUR 6.0 million) were achieved post-period end.

Risks and Contingencies

• Financial Market Turmoil: While operations remain stable, the global financial crisis creates a challenging financing environment. The company holds EUR 8.7 million in auction rate securities, which have been impaired by approximately 11.7%.
• Clinical Risk: Inherent risks of drug development failure and regulatory approval delays.
• Legal: A shareholder action was filed on October 21, 2008, seeking nullification of Supervisory Board resolutions; management considers this unsubstantiated.

Investor Verification Checklist

• Milestone Sustainability: Verify the timing and probability of future milestone payments from Boehringer Ingelheim and Roche, which heavily influence revenue guidance.
• Auction Rate Securities: Assess the liquidity risk and potential further impairment of the EUR 8.7 million holding in auction rate securities amidst market volatility.
• Renovis Integration: Monitor the integration costs and R&D burn rate associated with the Renovis acquisition.
• Partnership Execution: Track the status of the EVT 201 (insomnia) partnership discussions, as a deal could materially alter the cash runway.
• Currency Exposure: Evaluate the impact of EUR/USD and EUR/GBP exchange rate fluctuations on reported revenues and liquidity.